IDEAYA Biosciences (IDYA) Total Non-Current Liabilities (2018 - 2026)

IDEAYA Biosciences has reported Total Non-Current Liabilities for 9 years, with the latest figure at $93.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 21.66% year-over-year to $93.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.1 million (up 21.66% YoY) and the FY2025 annual result came in at $86.4 million, up 33.02% from the prior year.
• Total Non-Current Liabilities rose to $93.1 million in Q1 2026 per IDYA's latest filing, from $86.4 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $93.1 million in Q3 2025 and troughed at $24.9 million in Q3 2023.
• A 5-year average of $56.1 million and a median of $59.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities plunged 62.22% in 2023, then soared 191.83% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $38.5 million in 2022, then dropped by 26.71% to $28.2 million in 2023, then jumped by 130.09% to $64.9 million in 2024, then soared by 33.02% to $86.4 million in 2025, then climbed by 7.75% to $93.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $93.1 million, $86.4 million, and $93.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.